Comparing elritercept to epoetin alfa for anemia in MDS needing transfusions
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- 18 years or older with a diagnosis of very low-, low-, or intermediate-risk MDS.
- Need regular red blood cell transfusions (2–6 units every 8 weeks).
- Hemoglobin level below 11.0 g/dL after your last transfusion.
- Bone marrow has less than 5% blasts (immature cells).
- Endogenous erythropoietin level less than 500 U/L.
- No prior treatment with certain MDS therapies, including darbepoetin or luspatercept.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
This study tests whether a new drug called elritercept can help reduce the need for blood transfusions in adults with myelofibrosis (a bone marrow cancer) who are already taking ruxolitinib. The goal is to see if elritercept helps your body make more red blood cells naturally.
This trial compares three different medicines to see which works best for people with a blood condition called myelodysplasia (also called MDS) that causes anemia. It aims to find the safest and most effective option to improve blood counts and reduce symptoms like tiredness or shortness of breath.
This trial is testing a new medicine called HS-20106 to see if it can improve anemia (low red blood cells) for people with certain types of MDS. If it works, it might reduce the need for blood transfusions.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.